Abstract Objectives Discrete choice experiments (DCEs) are increasingly advocated as a
way to quantify preferences for health. However, increasing support does not necessarily …

Background Targeted pharmacotherapy has been increasingly applied in cancer treatment
due to its breakthroughs. However, the unmet needs of cancer patients are still significant …

Background As the number and type of cancer treatments available rises and patients live
with the consequences of their disease and treatments for longer, understanding …

Background Recently approved second‐generation androgen receptor inhibitors (SGARIs)
for non‐metastatic castration‐resistant prostate cancer (nmCRPC) have similar efficacy but …

Background Up to a fifth of patients diagnosed with prostate cancer (PC) will develop
castration-resistant prostate cancer (CRPC), which has been associated with a poor …

Purpose Patient treatment preferences are increasingly being used to inform health care
decision making. This discrete choice experiment assessed how men perceive the risks and …

Context Advances in systemic agents have increased overall survival for men diagnosed
with metastatic prostate cancer. Additional cytoreductive prostate treatments and metastasis …

Background Treatment options for patients with metastatic hormone-sensitive prostate
cancer (mHSPC) have broadened, and treatment decisions can have a long-lasting impact …

Background Recent approvals of second-generation androgen receptor inhibitors (SGARIs)
have changed the treatment landscape for non-metastatic castration-resistant prostate …

Purpose This study examined real-world long-term use of guideline-recommended bone
targeted agents (BTA) among patients with metastatic solid tumors. Methods Adults with a …